RHYTHM PHARMACEUTICALS, INC. Marketable Securities, Unrealized Gain (Loss)
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Marketable Securities, Unrealized Gain (Loss) of $488.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-02-26
- RHYTHM PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $488.00K.
- RHYTHM PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2025-03-31 was -$10.00K.
- RHYTHM PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2023-06-30 was $40.00K, a 73.91% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2023-03-31 was $65.00K.
- RHYTHM PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for fiscal 2023 was $366.00K.
- RHYTHM PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for fiscal 2021 was -$50.00K, a 202.04% decline from fiscal 2020.
- RHYTHM PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for fiscal 2020 was $49.00K, a 65.97% decline from fiscal 2019.
- RHYTHM PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for fiscal 2019 was $144.00K, a 1700.00% increase from fiscal 2018.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-09-30 | $488.00K 10-Q · filed 2025-11-04 | |||
| 2025-03-31 | -$10.00K 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $366.00K 10-K · filed 2026-02-26 | |||
| 2023-06-30 | $40.00K 10-Q · filed 2023-11-08 | $105.00K derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2023-03-31 | $65.00K 10-Q · filed 2023-11-08 | |||
| 2022-09-30 | $267.00K 10-Q · filed 2023-11-08 | $290.00K derived: sum of 2 quarters · filed 2023-11-08 | -$338.00K derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $23.00K 10-Q · filed 2023-11-08 | -$605.00K derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | -$628.00K 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | -$50.00K 10-K · filed 2022-03-01 | |||
| 2021-06-30 | $79.00K 10-Q · filed 2022-11-08 | -$28.00K derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | -$107.00K 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $49.00K 10-K · filed 2021-03-01 | |||
| 2020-09-30 | -$392.00K 10-Q · filed 2021-11-02 | $175.00K derived: sum of 2 quarters · filed 2021-11-02 | $238.00K derived: sum of 3 quarters · filed 2021-11-02 | |
| 2020-06-30 | $567.00K 10-Q · filed 2021-11-02 | $630.00K derived: sum of 2 quarters · filed 2021-11-02 | ||
| 2020-03-31 | $63.00K 10-Q · filed 2021-11-02 | |||
| 2019-12-31 | $144.00K 10-K · filed 2021-03-01 | |||
| 2019-09-30 | -$81.00K 10-Q · filed 2020-11-02 | |||
| 2019-03-31 | $214.00K 10-Q · filed 2020-11-02 | |||
| 2018-12-31 | $8.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |